Ajanta Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ajanta Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Ajanta Pharma from all sources in a single place.

Ajanta Pharma Ltd.

13 Jan 2026

2680.90

-0.94%

Company Update

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Pls find enclosed herewith Intimation w.r.t Formation of Subsidiary

pdf

Ajanta Pharma Ltd.

12 Jan 2026

2680.90

-0.94%

Company Update

Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pls find enclosed Investor Call Intimation

pdf

Ajanta Pharma Ltd.

12 Jan 2026

2680.90

-0.94%

Board Meeting

Ajanta Pharma Ltd - 532331 - Board Meeting Intimation for Considering Unaudited Financial Results For The …

BSE India

Ajanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve Unaudited Financial Results for quarter ended 31st December 2025.

pdf

Ajanta Pharma Ltd.

06 Jan 2026

2680.90

-0.94%

Company Update

Ajanta Pharma Ltd - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pls find enclosed Certificate as per Reg. 74(5) of SEBI (DP) Regulations, 2018.

pdf

Ajanta Pharma Ltd.

31 Dec 2025

2680.90

-0.94%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 31, 2025 for Aayush Agrawal, trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

31 Dec 2025

2680.90

-0.94%

Broker's call: Ajanta Pharma (Buy)

Business Line

Motilal Oswal

Number of FII/FPI investors decreased from 343 to 316 in Dec 2025 qtr

Ajanta Pharma Ltd.

30 Dec 2025

2680.90

-0.94%

SAST

Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 30, 2025 for Aayush Agrawal, trustee Aayush Agrawal Trust

pdf

Ajanta Pharma Ltd.

30 Dec 2025

2680.90

-0.94%

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism

Business Standard

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

Ajanta Pharma Ltd. is trading above its 200 day SMA of 2598.5

'Buy' Ajanta Pharma Shares Maintains Motilal Oswal, Sees 17% Upside Check Target Price

NDTV Profit | 30 Dec 2025

Ajanta Pharma Ltd.

29 Dec 2025

2680.90

-0.94%

Branded generics playbook fires; semaglutide adds a new growth leg

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP is implementing multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa to sustain robust industry outperformance.

Ajanta Pharma Ltd. is trading below its 30 day SMA of 2716.9

Ajanta Pharma Ltd.

26 Dec 2025

2680.90

-0.94%

Ajanta Pharma's growth story gets a semaglutide boost

livemint

Given Ajanta's improving business mix and robust cash generation, its share valuation appears reasonable for a company transitioning into a cleaner, higher-visibility healthcare compounder.

Ajanta Pharma Ltd. is trading above its 200 day SMA of 2598.5

Ajanta Pharma to generate healthy margins from Biocon deal: PL Capital

Business Standard | 26 Dec 2025

Is Ajanta Pharma Ltd. worth buying?

195 Votes:

Buy 76.92%

Sell 16.41%

Hold 6.67%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf